Bedrijfsoverzicht
bioAffinity Technologies, Inc. is a specialized entity within the healthcare sector, specifically focused on the diagnostics and research industry, where it develops non-invasive diagnostic laboratory tests aimed at detecting early-stage lung cancer and other pulmonary diseases. The company utilizes advanced methodologies such as flow cytometry and automated analysis to facilitate these diagnostic capabilities primarily within the United States. Operating through two distinct segments, namely Diagnostic Research and Development, the firm currently employs a workforce of 57 individuals to execute its operational strategy. As of the latest data, the company possesses a market capitalization of $15.07M and generated annual revenue of $6.16M, reflecting a relatively small-scale enterprise within the broader biotechnology landscape. These financial dimensions indicate that bioAffinity operates with a modest economic footprint, positioning it as a micro-cap or small-cap player that relies heavily on its proprietary technology and niche market positioning rather than diversified revenue streams or significant scale advantages typically associated with larger pharmaceutical corporations.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $6.16M, yet simultaneously recorded a net income of $-14,909,754 and an EBITDA of $-10,067,672, highlighting a substantial divergence between top-line sales and bottom-line profitability. The significant gap between the $6.16M revenue and the negative net income reveals a cost structure where operating expenses, likely driven by research and development costs in the diagnostics space, far exceed the gross revenues generated. This negative financial performance is further underscored by a free cash flow of $-4,933,569, which indicates that the company is burning cash and lacks the immediate financial flexibility to fund operations without external capital injections or financing activities. Margin analysis shows a gross margin of 31.4%, suggesting that while the cost of goods sold is managed relatively efficiently, the operating margin stands at a negative 196.9% and the profit margin at a negative 242.0%, implying that general and administrative costs are disproportionately high relative to sales. In terms of leverage, the company holds $6.45M in cash against $1.16M in debt, resulting in a debt-to-equity ratio of 15.95, which presents a complex balance sheet picture where high leverage metrics contrast with a net cash position. The current ratio of 2.60 suggests that the company maintains a robust level of short-term liquidity, as its current assets are more than double its current liabilities, providing a buffer against immediate solvency pressures. Furthermore, the return on equity is reported at -301.8% and the return on assets at -75.6%, metrics that reveal that management effectiveness, as measured by traditional profitability ratios, is currently negative due to the absence of earnings, which is typical for early-stage biotech firms focused on product development rather than profit generation.
Waarderingsbeoordeling
Valuation metrics for bioAffinity Technologies, Inc. present a challenging picture due to its lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -5.58, the latter implying that the market prices the stock based on future earnings expectations that are currently negative or undefined. The price-to-book ratio stands at 2.07, indicating that the market values the company at approximately twice its book value, which suggests a premium placed on its intangible assets, such as intellectual property and clinical trial data, despite the current lack of earnings. Alternative valuation multiples provide additional context, with a price-to-sales ratio of 2.45 and an EV/EBITDA of -0.97, suggesting that investors are willing to pay a significant multiple of sales for a company that is not yet generating positive cash flows from operations. Regarding price volatility, the stock has traded between a 52-week low of $0.69 and a 52-week high of $17.43, with the current market price situated significantly below the 52-week high, reflecting a substantial correction or underperformance relative to its recent peak. The beta of -0.81 indicates an inverse correlation with the broader market, meaning the stock tends to move opposite to the market index, offering a unique risk profile that differs from standard equities and suggesting high idiosyncratic risk rather than systematic market exposure.
Growth & Income
The company experienced a revenue growth year-over-year of -27.8%, while earnings growth is listed as N/A due to the negative earnings profile, illustrating a scenario where declining revenue further exacerbates the losses inherent in the business model. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders, implying that any potential earnings or cash reserves are entirely reinvested into research, development, and operational growth rather than being returned to investors. This reinvestment strategy is characteristic of biotechnology firms in the diagnostic research phase, where capital allocation is directed toward advancing pipeline assets rather than shareholder returns. The overall growth and income profile for bioAffinity Technologies, Inc. is defined by negative revenue momentum and a complete absence of dividend income, positioning the stock as a speculative play on future technological breakthroughs rather than a value or income investment.